Table 1.
Baseline patient demographics and disease characteristics by platelet doubling status in the overall cohort (n=126).
| Platelet Doubling (N=126) | P valuea | ||||
|---|---|---|---|---|---|
| No | Yes | ||||
| N (99) | % (78.6) | N (27) | % (21.4) | ||
| Age (median, range) | 72.0 (25-85) | 69.0 (48-87) | 0.69 | ||
| Gender | 0.81 | ||||
| Male | 70 | 70.7 | 18 | 66.7 | |
| Female | 29 | 29.3 | 9 | 33.3 | |
| ECOG performance status | 1.00 | ||||
| <2 | 87 | 87.9 | 24 | 88.9 | |
| ≥2 | 12 | 12.1 | 3 | 11.1 | |
| Disease | 0.98 | ||||
| MDS High/Intermediate-2 | 44 | 44.4 | 13 | 48.1 | |
| MDS Low/Intermediate-1 | 19 | 19.2 | 5 | 18.5 | |
| CMML | 4 | 4.0 | 1 | 3.7 | |
| Oligoblastic AML | 16 | 16.2 | 5 | 18.5 | |
| Non-oligoblastic AML | 16 | 16.2 | 3 | 11.1 | |
| Cytogenetics risk group by IPSS | 0.01 | ||||
| Favorable | 32 | 38.1 | 5 | 19.2 | |
| Intermediate | 17 | 20.2 | 0 | 0 | |
| Unfavorable | 30 | 35.7 | 17 | 65.4 | |
| Unacceptable for analysis | 5 | 6.0 | 4 | 15.4 | |
| Missing | 15 | - | 1 | - | |
| Presence of peripheral blood blasts | 0.09 | ||||
| No | 61 | 64.2 | 21 | 84.0 | |
| Yes | 34 | 35.8 | 4 | 16.0 | |
ECOG: Eastern Cooperative Oncology Group, IPSS: International Prognostic Scoring System, MDS: Myelodysplastic syndromes, CMML: Chronic myelomonocytic leukemia, AML-MRC: Acute myeloid leukemia with myelodysplasia-related changes.